These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12883337)

  • 21. Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway.
    Giannarelli C; Virdis A; De Negri F; Duranti E; Magagna A; Ghiadoni L; Salvetti A; Taddei S
    Hypertension; 2008 Aug; 52(2):314-21. PubMed ID: 18574075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of NG-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm.
    Cockcroft JR; Chowienczyk PJ; Brett SE; Ritter JM
    Br J Clin Pharmacol; 1994 Oct; 38(4):307-10. PubMed ID: 7530473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm.
    Jern C; Selin L; Tengborn L; Jern S
    Thromb Haemost; 1997 Aug; 78(2):887-91. PubMed ID: 9268190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm.
    Lembo G; Iaccarino G; Vecchione C; Barbato E; Izzo R; Fontana D; Trimarco B
    J Clin Invest; 1997 Oct; 100(8):2007-14. PubMed ID: 9329964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men.
    Pretorius M; Luther JM; Murphey LJ; Vaughan DE; Brown NJ
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2435-40. PubMed ID: 16166566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoking impairs bradykinin-stimulated t-PA release.
    Pretorius M; Rosenbaum DA; Lefebvre J; Vaughan DE; Brown NJ
    Hypertension; 2002 Mar; 39(3):767-71. PubMed ID: 11897760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contribution of nitric oxide and vasodilatory prostanoids to bradykinin-mediated vasodilation in Type 1 diabetes.
    Wotherspoon F; Browne DL; Meeking DR; Allard SE; Munday LJ; Shaw KM; Cummings MH
    Diabet Med; 2005 Jun; 22(6):697-702. PubMed ID: 15910619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
    Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
    Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
    Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
    Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
    Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
    J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension.
    Taddei S; Virdis A; Ghiadoni L; Magagna A; Favilla S; Pompella A; Salvetti A
    Hypertension; 2001 Mar; 37(3):943-8. PubMed ID: 11244022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
    Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ
    Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise.
    Van Guilder GP; Hoetzer GL; Smith DT; Irmiger HM; Greiner JJ; Stauffer BL; DeSouza CA
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E807-13. PubMed ID: 15985456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NG-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis.
    Fryburg DA
    J Clin Invest; 1996 Mar; 97(5):1319-28. PubMed ID: 8636445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism.
    Fong P; Stafforini DM; Brown NJ; Pretorius M
    Free Radic Biol Med; 2010 Jul; 49(2):301-5. PubMed ID: 20423727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired endogenous fibrinolytic capacity in prehypertensive men.
    Diehl KJ; Weil BR; Greiner JJ; Wright KP; Stauffer BL; DeSouza CA
    J Hum Hypertens; 2015 Aug; 29(8):468-72. PubMed ID: 25566873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide.
    Meredith IT; Currie KE; Anderson TJ; Roddy MA; Ganz P; Creager MA
    Am J Physiol; 1996 Apr; 270(4 Pt 2):H1435-40. PubMed ID: 8967386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation.
    Gilligan DM; Panza JA; Kilcoyne CM; Waclawiw MA; Casino PR; Quyyumi AA
    Circulation; 1994 Dec; 90(6):2853-8. PubMed ID: 7994830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reactive hyperemia and tissue-type plasminogen activator release in hypertensive men.
    Dell'Omo G; De Negri F; Carmassi F; Ruocco L; Mariani M; Pedrinelli R
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):19-25. PubMed ID: 12544724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
    Witherow FN; Dawson P; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2002 Sep; 40(5):961-6. PubMed ID: 12225723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.